Meeting
2023 ASCO Annual Meeting
OniLon: Phase II trial of trifluridine/tipiracil (TAS-102) and nanoliposomal irinotecan (nal-IRI) in advanced colorectal cancer.
Authors
Olatunji B. Alese
Winship Cancer Institute of Emory University, Atlanta, GA
Olatunji B. Alese , Olumide B. Gbolahan , Maria Diab , Gehan Botrus , Kathleen Coleman , Ashley McCook-Veal , Yuan Liu , Walid Labib Shaib , Christina Wu , Mehmet Akce , Bassel F. El-Rayes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03368963
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3580)
DOI
10.1200/JCO.2023.41.16_suppl.3580
Abstract #
3580
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.
First Author: Olatunji B. Alese
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: A phase II, single-arm study.
First Author: Xiaojing Xu